Diagnostic and Prognostic Markers of Severe and Cerebral Malaria
University Health Network - Technology Development and Commercialization
posted on 05/26/2010
Diagnostic and Prognostic Markers of Severe and Cerebral Malaria
Detailed Description
There are currently no simple laboratory tests to determine the severity of infection and to identify individuals at risk for developing cerebral malaria. Current diagnostic methods for cerebral malaria are based on clinical presentation and are unable to accurately differentiate cerebral malaria from neurological conditions or other infectious diseases. Furthermore, these methods cannot predict which patients presenting with uncomplicated malaria will go on to develop the cerebral form of the disease. A better diagnostic for cerebral malaria would allow greater accuracy in choice of treatment. A prognostic method for cerebral malaria would allow limited intensive therapeutic resources to be appropriately allocated to the small proportion of infected individuals who are at risk of developing severe and potentially deadly forms of the disease. This selective intervention has the potential to maximize the impact and effectiveness of limited health resources and to greatly reduce malaria deaths.
We have identified novel serum protein based biomarkers (ANG-1 and ANG-2) that correlate with disease severity and have shown high specificity and sensitivity for diagnosis of cerebral malaria (as high as 100%). These biomarkers can be measured with simple antibody based blood tests or other methods. Validation studies of these markers for prognosis of severe and cerebral malaria in large banked sample sets are underway.
Related Publication:
Lovegrove, F.E., et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One. 4(3), e4912 (2009)
File Number: 7010
Disease: Infectious Diseases
Other Information: PCT/CA2008/001939
Inventors: Kevin Kain, Conrad Liles, Fiona Lovegrove
This innovation currently is not available for online licensing. Please contact Thomas Parsons at University Health Network - Technology Development and Commercialization for more information.
Find more innovations
